PCI Biotech Holding ASA (LTS:0JGL) Current Accrued Expense: kr0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PCI Biotech Holding ASA Current Accrued Expense?

PCI Biotech Holding ASA LTS:0JGL Current Accrued Expense is kr0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's Current Accrued Expense for the quarter that ended in Dec. 2025 was kr0.00 Mil.

PCI Biotech Holding ASA's quarterly Current Accrued Expense declined from Dec. 2024 (kr2.47 Mil) to Jun. 2025 (kr Mil) but then increased from Jun. 2025 (kr Mil) to Dec. 2025 (kr0.00 Mil).

PCI Biotech Holding ASA's annual Current Accrued Expense increased from Dec. 2023 (kr0.84 Mil) to Dec. 2024 (kr2.47 Mil) but then declined from Dec. 2024 (kr2.47 Mil) to Dec. 2025 (kr0.00 Mil).

PCI Biotech Holding ASA Current Accrued Expense Related Terms

PCI Biotech Holding ASA Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Current Accrued Expense Chart

PCI Biotech Holding ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.84 2.47 0.00

PCI Biotech Holding ASA Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun24 Dec24 Jun25 Dec25
Current Accrued Expense Get a 7-Day Free Trial 0.07 - 2.47 - 0.00

PCI Biotech Holding ASA Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of kr0.00 Mil mean?
PCI Biotech Holding ASA (LTS:0JGL) has a Current Accrued Expense of kr0.00 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Current Accrued Expense too high?
PCI Biotech Holding ASA's current Current Accrued Expense is kr0.00 Mil.
How does PCI Biotech Holding ASA's Current Accrued Expense compare to VRTX and REGN?
PCI Biotech Holding ASA's Current Accrued Expense of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Current Accrued Expense is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (LTS:0JGL) has a current Current Accrued Expense of kr0.00 Mil. The current Current Accrued Expense is kr0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For PCI Biotech Holding ASA (LTS:0JGL), the current Current Accrued Expense is kr0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.